Toro Company vice president Amy Dahl to depart at end of September
On March 6, Amy Horton, the Vice President and Chief Accounting Officer of Artivion, Inc. (NYSE:AORT), executed a sale of 1,048 shares of the company’s common stock. The transaction was valued at approximately $25,995, with the shares sold at a price of $24.8044 each. The sale comes as Artivion, a nearly $1 billion market cap company, trades at $23.50, down about 15% year-to-date.
This sale was conducted to cover tax withholding obligations related to the vesting of performance stock units, as detailed in a footnote accompanying the transaction. Following this sale, Horton retains direct ownership of 146,651 shares of Artivion’s common stock. According to InvestingPro data, the company maintains a "GOOD" overall financial health score, though analysts have recently revised their earnings expectations downward.
Additionally, Horton acquired 10,261 shares through the vesting of performance stock units, which were granted on February 23, 2024. These shares were issued as part of a scheduled vesting plan, with future vesting dates set for 2026 and 2027, contingent upon continued employment.For deeper insights into Artivion’s valuation and growth prospects, InvestingPro subscribers can access 10+ additional ProTips and a comprehensive Pro Research Report, offering expert analysis of what really matters for this healthcare stock.
In other recent news, Artivion Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $97.3 million, which fell short of the forecasted $100.82 million. This revenue shortfall was attributed to a cybersecurity breach that impacted sales by approximately $4.5 million. Despite this, the company’s adjusted EBITDA for the fourth quarter exceeded expectations, reaching $17.6 million compared to the anticipated $17 million. Analysts from Stifel and Needham adjusted their price targets for Artivion, with Stifel lowering its target from $33 to $30, and Needham reducing its target from $34 to $32, both maintaining a Buy rating. JMP Securities, however, maintained its price target at $33 and a Market Outperform rating.
Artivion’s management projects first-quarter 2025 revenues between $94 million and $98 million, below previous estimates due to ongoing effects from the cyber incident. However, they anticipate a rebound in sales growth throughout 2025, projecting revenues between $420 million and $435 million, indicating a 10% to 14% increase. The company also expects its 2025 adjusted EBITDA to be between $83 million and $91 million, which is favorable compared to prior projections. Notably, the On-X product line experienced a 10% increase, while BioGlue sales rose by 7%, despite an 8% decline in Preservation Services. Artivion continues to focus on recovering from the cybersecurity disruption and aims to offset the first quarter’s challenges in subsequent quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.